Literature DB >> 19272518

Multiple sclerosis.

Ardith M Courtney1, Katherine Treadaway, Gina Remington, Elliot Frohman.   

Abstract

Multiple sclerosis is the most common disabling neurologic disease affecting young adults and adolescents in the United States. The first objective of this article is to familiarize nonspecialists with the cardinal features of multiple sclerosis and our current understanding of its etiology, epidemiology, and natural history. The second objective is to explain the approach to diagnosis. The third is to clarify current evidence-based treatment strategies and their roles in disease modification. The overall goal is to facilitate the timely evaluation and confirmation of diagnosis and enhance effective management through collaboration among primary physicians, neurologists, and other care providers who are confronted with these formidably challenging patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19272518     DOI: 10.1016/j.mcna.2008.09.014

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  11 in total

1.  Studies in experimental autoimmune encephalomyelitis do not support developmental bisphenol a exposure as an environmental factor in increasing multiple sclerosis risk.

Authors:  Dimitry N Krementsov; Anne Katchy; Laure K Case; Frances E Carr; Barbara Davis; Cecilia Williams; Cory Teuscher
Journal:  Toxicol Sci       Date:  2013-06-23       Impact factor: 4.849

2.  Symptom Co-occurrences Associated with Smoking in Individuals with Relapsing-Remitting Multiple Sclerosis.

Authors:  Pamela Newland; Louise Flick; Hong Xian; Florian P Thomas
Journal:  Int J MS Care       Date:  2016 Jul-Aug

3.  Multiple linked quantitative trait loci within the Tmevd2/Eae3 interval control the severity of experimental allergic encephalomyelitis in DBA/2J mice.

Authors:  K M Spach; L K Case; R Noubade; C B Petersen; B McElvany; N Zalik; W F Hickey; E P Blankenhorn; C Teuscher
Journal:  Genes Immun       Date:  2010-09-23       Impact factor: 2.676

4.  Updates on clinically isolated syndrome and diagnostic criteria for multiple sclerosis.

Authors:  Jacqueline F Marcus; Emmanuelle L Waubant
Journal:  Neurohospitalist       Date:  2013-04

Review 5.  Preclinical assessment of stem cell therapies for neurological diseases.

Authors:  Valerie L Joers; Marina E Emborg
Journal:  ILAR J       Date:  2009

6.  Quality of life outcomes following surgery for patients with coexistent cervical stenosis and multiple sclerosis.

Authors:  Daniel Lubelski; Matthew D Alvin; Michael Silverstein; Nilgun Senol; Kalil G Abdullah; Edward C Benzel; Thomas E Mroz
Journal:  Eur Spine J       Date:  2014-05-15       Impact factor: 3.134

7.  Clinical and economic impact of a specialty care management program among patients with multiple sclerosis: a cohort study.

Authors:  H Tan; J Yu; D Tabby; A Devries; J Singer
Journal:  Mult Scler       Date:  2010-07-01       Impact factor: 6.312

8.  The impact of comorbid depression on adherence to therapy for multiple sclerosis.

Authors:  M Tarrants; M Oleen-Burkey; J Castelli-Haley; M J Lage
Journal:  Mult Scler Int       Date:  2011-08-02

9.  Chronic cerebrospinal venous insufficiency in multiple sclerosis: clinical correlates from a multicentre study.

Authors:  Stefano Bastianello; Alfredo Romani; Gisela Viselner; Enrico Colli Tibaldi; Elisabetta Giugni; Marta Altieri; Pietro Cecconi; Laura Mendozzi; Massimiliano Farina; Donatella Mariani; Antonio Galassi; Claudio Quattrini; Marcello Mancini; Vincenzo Bresciamorra; Angela Lagace; Sandy McDonald; Giorgio Bono; Roberto Bergamaschi
Journal:  BMC Neurol       Date:  2011-10-26       Impact factor: 2.474

10.  Histamine H(3) receptor integrates peripheral inflammatory signals in the neurogenic control of immune responses and autoimmune disease susceptibility.

Authors:  Dimitry N Krementsov; Emma H Wall; Rebecca A Martin; Meenakumari Subramanian; Rajkumar Noubade; Roxana Del Rio; Gary M Mawe; Jeffrey P Bond; Matthew E Poynter; Elizabeth P Blankenhorn; Cory Teuscher
Journal:  PLoS One       Date:  2013-07-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.